Associations of Discomfort Intolerance, Discomfort Avoidance, and Cannabis and Alcohol Use Among Persons with Chronic Pain Receiving Prescription Buprenorphine for Opioid Use Disorder

Overview

Journal Drug Alcohol Depend

Publisher Elsevier

Specialty Psychiatry

Date 2024 Nov 3

PMID 39488941

Authors

Danielle F Haley

Michael D Stein

Sally Bendiks

Skylar Karzhevsky

Claire Pierce

Ana Dunn

Debra S Herman

Bradley Anderson

Risa B Weisberg

Affiliations

Soon will be listed here.

Abstract

Background: Chronic pain and non-prescribed substance use are associated with lower retention in opioid use disorder (OUD) treatment. We examined the associations of perceived capacity to tolerate uncomfortable physical sensations (discomfort intolerance and discomfort avoidance) and cannabis and alcohol use among persons with chronic pain receiving prescription buprenorphine for OUD.

Methods: This study utilizes baseline data from 163 persons with chronic pain receiving prescription buprenorphine for OUD enrolled in the Treating Opioid use, Persistent Pain, and Sadness (TOPPS) intervention trial. We used negative-binomial regression models, adjusted for age, education, gender, race/ethnicity, pain interference, depression, generalized anxiety disorder, and average cigarettes smoked/day to estimate the associations of discomfort tolerance and discomfort avoidance with frequency of cannabis and alcohol use.

Results: Participants (n=163) were on average 45 years old (standard deviation=10.6) and predominantly White (86 %, n=141). Forty-one percent (n=66) used cannabis and 24 % (n=30) used alcohol use in the past 30 days. In adjusted models, discomfort intolerance was positively associated with days of cannabis use (IRR = 1.11, p =.016) and days of alcohol use (IRR = 1.14, p =.022). Discomfort avoidance was not associated with cannabis or alcohol use.

Conclusion: Individuals with chronic pain receiving prescribed buprenorphine for treatment of OUD with lower tolerance for physical discomfort may augment pain management with cannabis and alcohol. Given the intersections between substance use and retention in care for OUD, future work should extend this preliminary work by exploring these relationships over time and in experimental settings. Clinical Trial # NCT03698669.

References

Fairley M, Humphreys K, Joyce V, Bounthavong M, Trafton J, Combs A . Cost-effectiveness of Treatments for Opioid Use Disorder. JAMA Psychiatry. 2021; 78(7):767-777. PMC: 8014209. DOI: 10.1001/jamapsychiatry.2021.0247. View

Wachholtz A, Gonzalez G . Co-morbid pain and opioid addiction: long term effect of opioid maintenance on acute pain. Drug Alcohol Depend. 2014; 145:143-9. PMC: 4254606. DOI: 10.1016/j.drugalcdep.2014.10.010. View

Lin L, Bohnert A, Blow F, Gordon A, Ignacio R, Kim H . Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration. Addiction. 2020; 116(1):96-104. DOI: 10.1111/add.15116. View

De La Rosa J, Brady B, Ibrahim M, Herder K, Wallace J, Padilla A . Co-occurrence of chronic pain and anxiety/depression symptoms in U.S. adults: prevalence, functional impacts, and opportunities. Pain. 2023; 165(3):666-673. PMC: 10859853. DOI: 10.1097/j.pain.0000000000003056. View

Buckner J, Keough M, Schmidt N . Problematic alcohol and cannabis use among young adults: the roles of depression and discomfort and distress tolerance. Addict Behav. 2007; 32(9):1957-63. PMC: 1986746. DOI: 10.1016/j.addbeh.2006.12.019. View

Klepp T, Heeren T, Winter M, Lloyd-Travaglini C, Magane K, Romero-Rodriguez E . Cannabis use frequency and pain interference among people with HIV. AIDS Care. 2023; 35(8):1235-1242. PMC: 10332422. DOI: 10.1080/09540121.2023.2208321. View

Kosiba J, Mitzel L, Zale E, Zvolensky M, Ditre J . A Preliminary Study of Associations between Discomfort Intolerance, Pain Severity/Interference, and Frequency of Cannabis Use among Individuals with Chronic Pain. Addict Res Theory. 2020; 28(1):76-81. PMC: 7540627. DOI: 10.1080/16066359.2019.1590557. View

Ferguson E, Lewis B, Teitelbaum S, Reisfield G, Robinson M, Boissoneault J . Longitudinal associations between pain and substance use disorder treatment outcomes. J Subst Abuse Treat. 2022; 143:108892. PMC: 11025107. DOI: 10.1016/j.jsat.2022.108892. View

Chua K, Nguyen T, Zhang J, Conti R, Lagisetty P, Bohnert A . Trends in Buprenorphine Initiation and Retention in the United States, 2016-2022. JAMA. 2023; 329(16):1402-1404. PMC: 10130945. DOI: 10.1001/jama.2023.1207. View

10.

Farrior H, Teitelbaum S, Phalin B, Janner A, Solomon L, Mathias K . Pain Predicts Dropout From Substance Use Treatment. J Stud Alcohol Drugs. 2024; 85(3):381-388. PMC: 11095491. DOI: 10.15288/jsad.23-00099. View

11.

Dong H, Stringfellow E, Russell W, Jalali M . Racial and Ethnic Disparities in Buprenorphine Treatment Duration in the US. JAMA Psychiatry. 2022; 80(1):93-95. PMC: 9647560. DOI: 10.1001/jamapsychiatry.2022.3673. View

12.

Kroenke K, Spitzer R, Williams J . The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-13. PMC: 1495268. DOI: 10.1046/j.1525-1497.2001.016009606.x. View

13.

Powers J, Zvolensky M, Ditre J . An integrative review of personalized feedback interventions for pain and alcohol. Curr Opin Psychol. 2019; 30:48-53. PMC: 6667314. DOI: 10.1016/j.copsyc.2019.01.013. View

14.

Stein M, Bendiks S, Karzhevsky S, Pierce C, Dunn A, Majeski A . Study protocol for the Treating Opioid Patients' Pain and Sadness (TOPPS) study - A randomized control trial to lower depression and chronic pain interference, and increase care retention among persons receiving buprenorphine. Contemp Clin Trials. 2024; 143:107608. DOI: 10.1016/j.cct.2024.107608. View

15.

Schmidt N, Richey J, Fitzpatrick K . Discomfort intolerance: Development of a construct and measure relevant to panic disorder. J Anxiety Disord. 2006; 20(3):263-80. DOI: 10.1016/j.janxdis.2005.02.002. View

16.

Spitzer R, Kroenke K, Williams J, Lowe B . A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006; 166(10):1092-7. DOI: 10.1001/archinte.166.10.1092. View

17.

Kuerbis A, Reid M, Lake J, Glasner-Edwards S, Jenkins J, Liao D . Daily factors driving daily substance use and chronic pain among older adults with HIV: An exploratory study using ecological momentary assessment. Alcohol. 2018; 77:31-39. PMC: 6456439. DOI: 10.1016/j.alcohol.2018.10.003. View

18.

Santo Jr T, Clark B, Hickman M, Grebely J, Campbell G, Sordo L . Association of Opioid Agonist Treatment With All-Cause Mortality and Specific Causes of Death Among People With Opioid Dependence: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2021; 78(9):979-993. PMC: 8173472. DOI: 10.1001/jamapsychiatry.2021.0976. View

19.

McDonagh M, Morasco B, Wagner J, Ahmed A, Fu R, Kansagara D . Cannabis-Based Products for Chronic Pain : A Systematic Review. Ann Intern Med. 2022; 175(8):1143-1153. DOI: 10.7326/M21-4520. View

20.

Zale E, Maisto S, Ditre J . Interrelations between pain and alcohol: An integrative review. Clin Psychol Rev. 2015; 37:57-71. PMC: 4385458. DOI: 10.1016/j.cpr.2015.02.005. View